Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Philadelphia Chromosome × bosutinib × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Philadelphia Chromosome 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Blast Crisis 1

Interventions

nilotinib 1 fludarabine 1 bosutinib 1 asciminib 1 Imatinib Mesylate 1 Dasatinib 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting

406 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡